Due to the high prevalence of lactose intolerance, lactase supple- ments increasingly gain popularity as they are known to improve the lactose digestion and reduce gastrointestinal symptoms. The aim of this study was to develop lactase tablets by a simple and robust direct compression process, which enables tableting of the moisture sensitive enzymes without the addition of water. Addi- tionally, this study aimed to simplify the formulation by using a two- component blend composed of API and only one ready-to-use ex- cipient, PROSOLV® EASYtab Nutra CM. The pure lactase powder was shown to be unsuitable for direct compression leading to tablets with insufficient tensile strength and high friability. Furthermore, the compression of pure lactase powder led to a significant loss of lactase activity by 20 – 40 %, depending on the compaction force. The addition of only 30 % of the high functionality excipient PROSOLV® EASYtab Nutra CM dramatically improved the tensile strength by almost tenfold. Furthermore, PROSOLV® EASYtab Nutra CM had positive effects on disintegration leading to a reduction of dis- integration time of more than 50 %. Due to the excellent compac- tability of PROSOLV® EASYtab Nutra CM, only a low compaction pressure of 5.75 kN was required to produce mechanically robust tablets which showed only 2.8 % loss of enzyme activity during tableting. Additionally, a comparison with marketed lactase tablets showed once again that PROSOLV® EASYtab Nutra CM is perfectly suited to produce lactase tablets with comparable or even better functional tablet properties. In contrast to the complex formulation of the marketed lactase tablets, the number of components in the PROSOLV® EASYtab based formulation could be reduced consider- ably to only two components, namely lactase powder and PROSOLV® EASYtab Nutra CM.